Clinical trials: sponsored by Almirall, S.A.
Plaque Psoriasis
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the…
- Trial name
- NCT06030076
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
Genital Psoriasis
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to…
- Trial name
- NCT06029257
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are…
- Trial name
- PROSES (NCT04820673)
- Testing
- Sarecycline
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
- Trial name
- PROAK (NCT05260073)
- Testing
- Tirbanibulin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100…
- Trial name
- TRIBUTE (NCT04229836)
- Testing
- Tildrakizumab 100 mg Solution for Injection
- Where
- 39 sites in Italy, Spain
- Volunteers
- 178 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
UV Sensor in Patients With Actinic Keratosis
To validate the use of Ultraviolet (UV) radiation sensor in patients with actinic keratosis, to identify barriers to its use in prospective longitudinal studies.
- Trial name
- NCT05481073
- Testing
- UV sensor
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
The purpose of this study is to assess the efficacy, safety and tolerability of Tildrakizumab in moderate-to-severe plaque psoriasis participants who are non-responder to Dimethyl fumarate (DMF) at Week 16.
- Trial name
- TRANSITION (NCT04263610)
- Testing
- Dimethyl fumarate (DMF) standard scheme, Dimethyl fumarate (DMF) simplified scheme, Tildrakizumab
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Almirall, S.A.
Recurrent Respiratory Tract Infections
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)
The purpose of this study is to assess the efficacy of pidotimod as treatment in participants with recurrent respiratory tract infections.
- Trial name
- P-CRESCENT (NCT04322669)
- Testing
- Pidotimod
- Where
- 16 sites in China
- Volunteers
- 338 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory…
- Trial name
- MODIFY (NCT04339595)
- Testing
- Tildrakizumab
- Where
- 3 sites in Poland
- Volunteers
- 47 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the…
- Trial name
- NCT03285490
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
- Trial name
- NCT02959970
- Testing
- dapsone gel
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02320149
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 968 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
- Trial name
- NCT01628549
- Testing
- 50 mg P005672-HCl, 100 mg P005672-HCl
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02322866
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 1,034 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
- Trial name
- NCT02413346
- Testing
- Sarecycline
- Where
- 56 sites in United States
- Volunteers
- 490 people
- Sponsor
- Almirall, S.A.
Healthy Volunteers
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
This study will evaluate the potential of dapsone gel and its vehicle to cause a photoallergic reaction after repeated application and irradiation to the skin of healthy volunteers under controlled conditions.
- Trial name
- NCT02117739
- Testing
- dapsone gel, dapsone gel vehicle
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Healthy Volunteers
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
This study will determine the cumulative irritation potential and sensitization potential of dapsone gel and vehicle after repeat applications on the skin of healthy volunteers.
- Trial name
- NCT02117752
- Testing
- dapsone gel, dapsone gel vehicle, sodium lauryl sulfate
- Where
- United States
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.